Data from recent phase 3 clinical trials show that for some patients with lung cancer, targeted therapies and other treatment regimens can achieve slight improvements in survival over current standards of care. But so far, the impact of such therapies on extending life or slowing disease progression has been modest, although some regimens may be less toxic to patients.
Researchers discussed the findings at the recent 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), in Orlando, Fla.
Hampton T. Lung Cancer Trials Probe Effects of Maintenance Therapy, Targeted Agents. JAMA. 2009;302(6):616-618. doi:10.1001/jama.2009.1118